Screener / SEC EDGAR /CIK 0001649094 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Vaxcyte, Inc. PCVX

Compare with peers Embed
Planned sales, announced before they happen

5 trading plans running, 27 Form 144 notices for $13.9M

10-Q, 10-K and Form 144
Plans running now 5 Harp Dhaliwal, Andrew Guggenhime, Grant Pickering, Jim Wassil, Elvia Cowan
Plans adopted 18 reported since May 8, 2023 Form 144 notices 27 $13.9M the sellers expected to sell

What PCVX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 17, 2024 to Aug 15, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Harp Dhaliwal
Chief Technical Operations Officer
Adopted 10b5-1 plan Apr 6, 2026 10-Q Aug 5, 2026
What the company wrote
Harp Dhaliwal, our Chief Technical Operations Officer, adopted a 10b5-1 Plan on April 6, 2026, with an effective date of August 5, 2026. Mr. Dhaliwal’s 10b5-1 Plan provides for the potential exercise and sale of up to 68,000 shares of our common stock, and expires on August 15, 2027, or upon the earlier completion of all authorized transactions thereunder.
Andrew Guggenhime
President and Chief Financial Officer
Adopted 10b5-1 plan Mar 4, 2026 10-Q May 6, 2026
What the company wrote
Andrew Guggenhime, our President and Chief Financial Officer, adopted a 10b5-1 Plan on March 4, 2026, with an effective date of June 3, 2026. Mr. Guggenhime’s 10b5-1 Plan provides for the potential exercise and sale of up to 156,000 shares of our common stock, and expires on June 30, 2027, or upon the earlier completion of all authorized transactions thereunder.
Grant Pickering
Chief Executive Officer and a member of our Board
Adopted 10b5-1 plan Mar 3, 2026 10-Q May 6, 2026
Jim Wassil
Executive Vice President, Chief Operating Officer
Adopted 10b5-1 plan Dec 9, 2025 10-K Feb 24, 2026
What the company wrote
Jim Wassil, our Executive Vice President, Chief Operating Officer, adopted a 10b5-1 Plan on December 9, 2025, with an effective date of March 10, 2026. Mr. Wassil’s 10b5-1 Plan provides for the potential exercise and sale of up to 70,056 shares of our common stock, and expires on March 1, 2027, or upon the earlier completion of all authorized transactions thereunder.
Elvia Cowan
Senior Vice President of Finance and Principal Accounting Officer
Adopted 10b5-1 plan Dec 8, 2025 10-K Feb 24, 2026
What the company wrote
Elvia Cowan, our Senior Vice President of Finance and Principal Accounting Officer, adopted a 10b5-1 Plan on December 8, 2025, with an effective date of March 10, 2026. Ms. Cowan’s 10b5-1 Plan provides for the potential exercise and sale of up to 41,060 shares of our common stock, and expires on February 28, 2027, or upon the earlier completion of all authorized transactions thereunder.
Peter Hirth
member of our Board
Ended 10b5-1 plan May 28, 2025 10-Q Aug 6, 2025
What the company wrote
On May 28, 2025, Peter Hirth, who was a member of our Board at the time, terminated his 10b5-1 Plan. Dr. Hirth's 10b5-1 Plan was originally adopted on December 6, 2024, with an effective date of March 7, 2025, for the potential exercise and sale of up to 13,200 shares of our common stock until March 31, 2026, or upon the earlier completion of all authorized transactions thereunder.
Andrew Guggenhime
President and Chief Financial Officer
Ended 10b5-1 plan Mar 17, 2025 10-Q May 7, 2025
What the company wrote
Andrew Guggenhime, our President and Chief Financial Officer, terminated his 10b5-1 Plan on March 17, 2025. Mr. Guggenhime’s 10b5-1 Plan was originally adopted on May 17, 2024, with an effective date of October 18, 2024, for the potential exercise and sale of up to 146,000 shares of our common stock, until October 17, 2025, or upon the earlier completion of all authorized transactions thereunder.
Grant Pickering
Chief Executive Officer
Ended 10b5-1 plan Dec 31, 2024 10-K Feb 25, 2025
What the company wrote
Grant Pickering, our Chief Executive Officer and a member of our Board, terminated his 10b5-1 Plan on December 31, 2024. Mr. Pickering’s 10b5-1 Plan was originally adopted on April 12, 2024 for the potential sale of (i) up to 45,000 shares of our common stock held by Mr. Pickering and the potential exercise and sale of up to 195,000 shares of our common stock held by Mr. Pickering, and (ii) up to 35,490 shares of our common stock held by trusts in which the beneficiaries are children of Mr. Pickering, until October 1, 2025, or upon the earlier completion of all authorized transactions thereunder.
Peter Hirth
member of our Board
Adopted 10b5-1 plan Dec 6, 2024 10-K Feb 25, 2025
What the company wrote
Peter Hirth, a member of our Board, adopted a 10b5-1 Plan on December 6, 2024, with an effective date of March 7, 2025. Dr. Hirth’s 10b5-1 Plan provides for the potential exercise and sale of up to 13,200 shares of our common stock, and expires on March 31, 2026, or upon the earlier completion of all authorized transactions thereunder.
Elvia Cowan
Senior Vice President of Finance and Principal Accounting Officer
Adopted 10b5-1 plan Sep 27, 2024 10-Q Nov 5, 2024
Teri Loxam
member of our Board
Adopted 10b5-1 plan Jun 18, 2024 10-Q Aug 6, 2024
What the company wrote
Teri Loxam, a member of our Board, adopted a 10b5-1 Plan on June 18, 2024, with an effective date of September 16, 2024. Ms. Loxam’s 10b5-1 Plan provides for the potential exercise and sale of up to 12,500 shares of our common stock, and expires on September 15, 2025, or upon the earlier completion of all authorized transactions thereunder.
Halley Gilbert
member of our Board
Ended 10b5-1 plan Jun 16, 2024 10-Q Aug 6, 2024
What the company wrote
Halley Gilbert, a member of our Board, terminated her 10b5-1 Plan on June 16, 2024. Ms. Gilbert’s 10b5-1 Plan was originally adopted on March 1, 2024 for the potential exercise and sale of up to 51,950 shares of our common stock until May 31, 2025, or upon the earlier completion of all authorized transactions thereunder.
Mikhail Eydelman
General Counsel, Chief Compliance Officer
Adopted 10b5-1 plan Jun 11, 2024 10-Q Aug 6, 2024
What the company wrote
Mikhail Eydelman, our General Counsel, Chief Compliance Officer and Corporate Secretary, adopted a 10b5-1 Plan on June 11, 2024, with an effective date of October 1, 2024. Mr. Eydelman’s 10b5-1 Plan provides for the potential exercise and sale of up to 65,500 shares of our common stock, and expires on September 30, 2025, or upon the earlier completion of all authorized transactions thereunder.
Andrew Guggenhime
President and Chief Financial Officer
Adopted 10b5-1 plan May 17, 2024 10-Q Aug 6, 2024
What the company wrote
Andrew Guggenhime, our President and Chief Financial Officer, adopted a 10b5-1 Plan on May 17, 2024, with an effective date of October 18, 2024. Mr. Guggenhime’s 10b5-1 Plan provides for the potential exercise and sale of up to 146,000 shares of our common stock, and expires on October 17, 2025, or upon the earlier completion of all authorized transactions thereunder.
Grant Pickering
Chief Executive Officer and a member of our Board
Adopted 10b5-1 plan Apr 12, 2024 10-Q Aug 6, 2024
What the company wrote
Grant Pickering, our Chief Executive Officer and a member of our Board, adopted a 10b5-1 Plan on April 12, 2024, with an effective date of October 1, 2024. Mr. Pickering’s 10b5-1 Plan provides for the potential sale of up to 45,000 shares of our common stock held by Mr. Pickering and the potential exercise and sale of up to 195,000 shares of our common stock held by Mr. Pickering. Mr. Pickering’s 10b5-1 Plan also provides for the potential sale of up to 35,490 shares of our common stock held by trusts in which the beneficiaries are children of Mr. Pickering. Mr. Pickering's 10b5-1 Plan expires on October 1, 2025, or upon the earlier completion of all authorized transactions thereunder.
Halley Gilbert
Board and Audit Committee member
Adopted 10b5-1 plan Mar 1, 2024 10-Q May 8, 2024
What the company wrote
Halley Gilbert, our Board and Audit Committee member, adopted a 10b5-1 Plan on March 1, 2024. Ms. Gilbert’s 10b5-1 Plan provides for the potential exercise and sale of up to 51,950 shares of our common stock, and expires on May 31, 2025, or upon the earlier completion of all authorized transactions thereunder.
Jim Wassil
Chief Operating Officer
Adopted 10b5-1 plan Mar 1, 2024 10-Q May 8, 2024
What the company wrote
Jim Wassil, our Chief Operating Officer, adopted a 10b5-1 Plan on March 1, 2024. Mr. Wassil’s 10b5-1 Plan provides for the potential exercise and sale of up to 108,000 shares of our common stock, and expires on September 1, 2025, or upon the earlier completion of all authorized transactions thereunder.
Andrew Guggenhime
President and Chief Financial Officer
Adopted 10b5-1 plan Jun 30, 2023 10-Q Aug 8, 2023
Mikhail Eydelman
Senior Vice President, General Counsel and Corporate Secretary
Adopted 10b5-1 plan Jun 29, 2023 10-Q Aug 8, 2023
Grant E. Pickering
Chief Executive Officer and a member of our Board
Adopted 10b5-1 plan Jun 26, 2023 10-Q Aug 8, 2023
Jim Wassil
Executive Vice President and Chief Operating Officer
Adopted 10b5-1 plan May 23, 2023 10-Q Aug 8, 2023
Heath Lukatch
member of our Board
Adopted 10b5-1 plan May 11, 2023 10-Q Aug 8, 2023
Show the other 14 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 12, 2026 Dhaliwal Harpreet S.
Officer
17,000 $1.2M
Nov 2, 2026 Wassil Jim
Officer
2,250 $139K
Nov 2, 2026 Cowan Elvia
Officer
3,000 $186K
Oct 5, 2026 Cowan Elvia
Officer
19,000 $1.6M
Oct 5, 2026 Wassil Jim
Officer
18,000 $1.6M
Oct 1, 2026 Wassil Jim
Officer
2,250 $128K
Sep 9, 2026 Wassil Jim
Officer
1,334 $80K
Sep 4, 2026 Wassil Jim
Officer
1,381 $82K
Sep 1, 2026 Wassil Jim
Officer
3,477 $210K
Aug 5, 2026 Dhaliwal Harpreet S.
Officer
17,000 $935K
Aug 3, 2026 GUGGENHIME ANDREW
Officer
10,000 $540K
Aug 3, 2026 Wassil Jim
Officer
2,250 $121K
Jul 27, 2026 PICKERING GRANT
Officer, Director
18,198 $997K
Jul 6, 2026 GUGGENHIME ANDREW
Officer
10,000 $578K
Jul 1, 2026 Wassil Jim
Officer
2,250 $131K
Jun 26, 2026 PICKERING GRANT
Officer, Director
24,237 $1.3M
Jun 18, 2026 GUGGENHIME ANDREW
Officer
10,000 $530K
Jun 18, 2026 PICKERING GRANT
Officer
24,461 $1.3M
Jun 1, 2026 Wassil Jim
Officer
2,250 $115K
May 1, 2026 Wassil Jim
Officer
2,250 $129K
Apr 7, 2026 Cowan Elvia
Officer
3,000 $180K
Apr 1, 2026 Wassil Jim
Officer
2,250 $131K
Mar 17, 2026 Cowan Elvia
Officer
1,892 $106K
Mar 11, 2026 Cowan Elvia
Officer
2,500 $147K
Mar 10, 2026 Wassil Jim
Officer
7,395 $432K
Dec 31, 2025 HARPREET DHALIWAL
Officer
9,743 $455K
Dec 23, 2025 ELVIA COWAN
Officer
11,623 $557K
Show the other 19 notices

From the Form 144 XML filed with the SEC, since Dec 23, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PCVX/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.